Like_老虎社区_美港股上老虎

Parangccyman
2021-08-23

Inclusion of Kintor as a Constituent Stock of HSCI

SUZHOU, China, Aug. 22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9

Inclusion of Kintor as a Constituent Stock of HSCI

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":835053290,"tweetId":"835053290","gmtCreate":1629681827110,"gmtModify":1633683278504,"author":{"id":4090061934789860,"idStr":"4090061934789860","authorId":4090061934789860,"authorIdStr":"4090061934789860","name":"Parangccyman","avatar":"https://static.tigerbbs.com/6096c16dea525df8d2da4a3ab4ad785d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/835053290","repostId":2161283427,"repostType":4,"repost":{"id":"2161283427","pubTimestamp":1629681000,"share":"https://www.laohu8.com/m/news/2161283427?lang=&edition=full","pubTime":"2021-08-23 09:10","market":"hk","language":"en","title":"Inclusion of Kintor as a Constituent Stock of HSCI","url":"https://stock-news.laohu8.com/highlight/detail?id=2161283427","media":"StreetInsider","summary":"SUZHOU, China, Aug. 22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (\"Kintor Pharma\", HKEX: 9","content":"<p>SUZHOU, China, Aug. 22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (\"Kintor Pharma\", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hang Seng Composite Index, effective September 6, 2021.</p>\n<p>Hang Seng Composite Index (HSCI) is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the important indexes in the Hong Kong equity market. This index offers a comprehensive Hong Kong market benchmark that covers the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong. Adopting the free-float-adjusted market capitalization methodology, the HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks.</p>\n<p>Dr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, \"The inclusion of Kintor Pharma as a constituent stock of the HSCI reflects the recognition and confidence in our company's business and development prospects from the capital markets. This inclusion indicates that Kintor Pharma's stock is eligible for trading via the Hong Kong-Shanghai Stock Connect link between China's mainland markets and the Hong Kong Exchange. We believe the liquidity of our stock and expansion of our investors base will benefit from this event. We will further advance the progress of our R&amp;D, clinical operations and commercialization efforts, in this way, to continue innovation on therapeutics for patients and maximize value for our shareholders.\"</p>\n<p><b>About Kintor Pharmaceutical Limited</b></p>\n<p>Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more information, visit www.kintor.com.cn.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inclusion of Kintor as a Constituent Stock of HSCI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInclusion of Kintor as a Constituent Stock of HSCI\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-23 09:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18848251><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SUZHOU, China, Aug. 22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (\"Kintor Pharma\", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18848251\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18848251","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161283427","content_text":"SUZHOU, China, Aug. 22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (\"Kintor Pharma\", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hang Seng Composite Index, effective September 6, 2021.\nHang Seng Composite Index (HSCI) is one of the important indexes in the Hong Kong equity market. This index offers a comprehensive Hong Kong market benchmark that covers the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong. Adopting the free-float-adjusted market capitalization methodology, the HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks.\nDr. Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented, \"The inclusion of Kintor Pharma as a constituent stock of the HSCI reflects the recognition and confidence in our company's business and development prospects from the capital markets. This inclusion indicates that Kintor Pharma's stock is eligible for trading via the Hong Kong-Shanghai Stock Connect link between China's mainland markets and the Hong Kong Exchange. We believe the liquidity of our stock and expansion of our investors base will benefit from this event. We will further advance the progress of our R&D, clinical operations and commercialization efforts, in this way, to continue innovation on therapeutics for patients and maximize value for our shareholders.\"\nAbout Kintor Pharmaceutical Limited\nKintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia, and acne. For more information, visit www.kintor.com.cn.","news_type":1},"isVote":1,"tweetType":1,"viewCount":25,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}